Labcorp has closed its purchase of Millennium Health and put a number on it for the first time. A regulatory filing shows $245 million in cash at signing plus up to $130 million tied to future events the company did not describe. The October 23 announcement carried no terms.
Millennium Health runs a specialty laboratory for drug monitoring. It sells urine and oral fluid tests for prescription, over the counter and illicit drugs. Labcorp said the business widens its toxicology menu and its geographic reach.
This is the fourth lab deal Labcorp has signed since September. The others were MLM Medical Labs, up to $872 million of BioReference Health assets, and Myriad Genetics' prenatal testing unit for $210 million. Chief executive Adam Schechter tied the run to the Protecting Access to Medicare Act, which squeezes smaller hospital and regional labs.
Two thirds of the maximum price landed at closing. The rest rides on milestones nobody outside the deal can see, which is how a buyer prices a toxicology book that moves with payer behavior.